SMITH & NEPHEW PLC (SNN) Form 6-K — Aug 4, 2026
Smith & Nephew reported first-half revenue of $3,097 million, with underlying growth of 2.3%, leading the company to reduce its full-year revenue growth guidance from approximately 6% to around 4%. The performance was impacted by softer demand in US Orthopaedics and Advanced Wound Bioactives, partly offset by strong growth in Sports Medicine and Emerging Markets. Despite the revenue reduction, the company reaffirmed its full-year guidance for trading profit growth of around 8%, free cash flow of approximately $800 million, and an adjusted ROIC of more than 10%.
Key figures
- Eps
- 35.6¢
- Revenue
- 3097
- Net Income
- 303
- Total Debt
- 3,019
- Cash Position
- 754
- Revenue Growth
- 2.3%
- Shares Outstanding
- 0
- Eps A cents
- 47.7
- Free Cash Flow
- 231
- Trading Profit
- 566
- Net Debt To EBITDA ratio
- 1.8
- Dividend Per Share cents
- 15.6
- Buyback Settled millions
- 216
- Buyback Authorized millions
- 500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.